GSK strikes $2.2bn deal to resolve legal cases in US over heartburn treatment Zantac

The British drugmaker GSK has struck an agreement to make a payment of up to $2.2bn (£1.7bn) to resolve litigation brought in the US over its heartburn treatment Zantac. The company said it had struck agreements with 10 plaintiff law firms who represent about 93%, roughly 80,000, of the US state court product liability cases pending against it. The company said in a stock market statement on Wednesday that it would make the aggregate payment to resolve all such cases handled by those plaintiff firms that me ...